Todd Asset Management LLC Has $4.24 Million Stake in Novo Nordisk A/S $NVO

Todd Asset Management LLC lifted its stake in Novo Nordisk A/S (NYSE:NVO) by 35.8% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 83,329 shares of the company’s stock after purchasing an additional 21,957 shares during the quarter. Todd Asset Management LLC’s holdings in Novo Nordisk A/S were worth $4,240,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Frazier Financial Advisors LLC raised its holdings in Novo Nordisk A/S by 52.9% in the 4th quarter. Frazier Financial Advisors LLC now owns 4,478 shares of the company’s stock valued at $228,000 after acquiring an additional 1,550 shares in the last quarter. Prospera Financial Services Inc raised its stake in Novo Nordisk A/S by 5.0% in the fourth quarter. Prospera Financial Services Inc now owns 441,858 shares of the company’s stock valued at $22,483,000 after purchasing an additional 21,063 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in Novo Nordisk A/S by 47.6% in the fourth quarter. EverSource Wealth Advisors LLC now owns 5,452 shares of the company’s stock valued at $277,000 after purchasing an additional 1,757 shares in the last quarter. Americana Partners LLC lifted its position in Novo Nordisk A/S by 21.4% during the fourth quarter. Americana Partners LLC now owns 70,807 shares of the company’s stock worth $3,603,000 after purchasing an additional 12,464 shares during the period. Finally, Markel Group Inc. increased its holdings in Novo Nordisk A/S by 21.2% in the 4th quarter. Markel Group Inc. now owns 2,869,774 shares of the company’s stock valued at $146,014,000 after buying an additional 501,125 shares during the period. Institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently issued reports on NVO. Morgan Stanley raised Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price objective for the company in a research note on Tuesday, March 3rd. Jefferies Financial Group raised shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research note on Thursday, February 12th. Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. Nordea Equity Research lowered Novo Nordisk A/S to a “hold” rating in a research report on Tuesday, February 24th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 24th. Four analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S Stock Down 0.1%

Shares of Novo Nordisk A/S stock opened at $44.91 on Tuesday. The stock’s 50-day moving average is $40.43 and its 200 day moving average is $46.42. Novo Nordisk A/S has a one year low of $35.12 and a one year high of $81.44. The firm has a market cap of $200.52 billion, a price-to-earnings ratio of 10.54, a PEG ratio of 4.01 and a beta of 0.77. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The business had revenue of $10.85 billion during the quarter. Equities research analysts anticipate that Novo Nordisk A/S will post 3.46 EPS for the current year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.